DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001

EyePoint Pharmaceuticals, Inc.527 enrolled

Overview

Retrospective study to provide clinical outcomes with DEXYCU (dexamethasone intraocular suspension) 9%.

This retrospective study is intended to provide large-scale, real-world data on clinical outcomes with DEXYCU (dexamethasone intraocular suspension) 9%.

Study Type

OBSERVATIONAL

Enrollment

527

Conditions

Cataract

Interventions

DEXYCU (dexamethasone intraocular suspension) 9%.DRUG

DEXYCU contains dexamethasone 9% w/w (103.4 mg/mL) as a sterile suspension for intraocular ophthalmic administration. DEXYCU is provided as a kit for administration of a single dose of 0.005 mL of 9% dexamethasone (equivalent to 517 micrograms of dexamethasone).

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria * Male and Female subjects at least 18 years of age * Subjects who underwent cataract surgery from 12Mar2019 to 15Dec2019 and received DEXYCU Exclusion Criteria • Subjects who underwent cataract surgery and did not receive DEXYCU

Locations (22)

Eye Center South Locations

Dothan, Alabama, United States

Outcomes

Primary Outcomes

Percentage of Eyes With Anterior Chamber Cell Grade 0

Of eyes with a record at postoperative day 8, percentage with anterior chamber cell grade 0. Cells in the anterior chamber of the eye are indicative of intraocular inflammation and are evaluated using a slit-lamp biomicroscope; a grade of 0 indicates that no inflammatory cells were visible in a 1 mm by 1 mm slit beam.

Time frame: Postoperative day 8

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.